Arrowhead agreement with Merck tied to new peptide library
This article was originally published in Scrip
Executive Summary
Arrowhead Research's recent agreement with Merck is the Pasadena, California-based company's first collaboration tied to a monoclonal antibody developed with the human-derived library of targeting peptides and novel receptors that Arrowhead acquired through the purchase of Alvos Therapeutics in April (scripintelligence.com, 12 April 2012).
You may also be interested in...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse
Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.
Need a specific report? 1000+ reports available
Buy Reports